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14 ABSTRACT: Important links exist between the process of
15 pre-mRNA splicing and cancer, as illustrated by the frequent
16 mutation of splicing factors in tumors and the emergence of
17 various families of antitumor drugs that target components of
18 the splicing machinery, notably SF3B1, a protein subunit of
19 spliceosomal U2 small nuclear ribonucleoprotein particle
20 (snRNP). Sudemycins are synthetic compounds that harbor
21 a pharmacophore common to various classes of splicing
22 inhibitors. Here, we describe the synthesis and functional
23 characterization of novel sudemycin analogues that function-
24 ally probe key functional groups within this pharmacophore.
25 Our results conﬁrm the importance of a conjugated diene
26 group and in addition reveal signiﬁcant spatial ﬂexibility in this
27 region of the molecule. Sudemycin K, a derivative that replaces
28 the pharmacophore’s oxycarbonyl by an amide group, displays improved potency as an inhibitor of cancer cell proliferation, as a
29 regulator of alternative splicing in cultured cells and as an inhibitor of in vitro spliceosome assembly. Sudemycin K displays higher
30 stability, likely related to the replacement of the oxycarbonyl group, which can be a substrate of esterases, by an amide group. The
31 activity and special reactivity of sudemycin K can pave the way to the synthesis and evaluation of a variety of novel sudemycin
32 derivatives.
33 The high incidence of cancer and severe limitations in34 current therapies (e.g., side eﬀects and drug resistance)
35 make the identiﬁcation of new drugs and targets an area of
36 intense investigation in oncology. Several small molecules
37 targeting components of the RNA splicing machinery have
38 been shown to display antitumor properties.1−3 Of relevance,
39 recent ﬁndings indicate that the splicing machinery can indeed
40 be limiting for the proliferation of cancer cells, and
41 consequently splicing inhibition can confer therapeutic
42 vulnerability to Myc oncogene-driven cancers.4,5
43 RNA splicing is the process by which introns are removed
44 from mRNA precursors (pre-mRNAs) and is achieved by the
45 spliceosome, composed of ﬁve small nuclear RiboNucleoPro-
46 tein complexes (U1, U2, U4, U5, and U6 snRNPs) and more
47 than 200 additional polypeptides.6,7 Introns are recognized via
48 speciﬁc sequence signals located at their boundaries: a short
49 (6−8 nucleotides) consensus at the 5′ splice site (5′ss) and
50three sequence elements at the 3′ splice site (3′ss). The latter
51include the branch point sequence (containing an adenosine
52involved in 2′−5′ phosphodiester bond formation with the 5′
53end of the intron after the ﬁrst catalytic step of the splicing
54reaction), a polypyrimidine tract, and a conserved AG
55dinucleotide at the 3′ end of the intron. The ﬁrst steps of
56spliceosome assembly include the recognition of the 5′ss by U1
57snRNP and of the branch point sequence by U2 snRNP, both
58involving base-pairing interactions between the corresponding
59small RNA components (snRNAs) and the pre-mRNA.6,7
60SF3B1 is a protein component of SF3B, a subcomplex within
61U2 snRNP implicated in branch point recognition. Mutations
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62 in SF3B1, as well as in other 3′ splice site-recognizing factors,
63 are recurrent in cancer.1,8 SF3B1 mutations are particularly
64 frequent in myelodysplastic syndromes with refractory anemia
65 and ring sideroblasts (RARS)9,10 and in chronic lymphocytic
66 leukemia (CLL).11−13 In CLL, SF3B1 mutants correlate with
67 resistance to chemotherapy and poor prognosis.11−13 Notably,
68 SF3B1 was identiﬁed as the physical target of drugs that display
69 higher cytotoxicity in tumor cells than in normal cells and are
70 therefore promising therapeutic candidates.1,14−18
71 Several natural compounds isolated from bacterial fermenta-
72 tion products display these properties, including FR901464,
73 pladienolides, FD-895, GEX1A, herboxidiene, and thailansta-
74 tines.19−23 Stabilized derivatives SSA (spliceostatin A,
75 FR901464-related) and E7107 (pladienolide-related) were
76 shown to inhibit splicing and bind tightly to the SF3B
77 complex.17,18 Similar results were obtained for herboxidiene.15
78 Thus, the SF3B complex has emerged as a target of
79 representative drugs in each of the three main classes of
80 natural compounds (spliceostatin, pladienolides, and herbox-
81 idienes). The spliceostatin analogue meayamycin was shown to
82 display antitumor eﬀects at picomolar concentrations.14
83 The drug spliceostatin A binds SF3B1 and prevents its
84 interaction with the pre-mRNA, concomitant with interactions
85 of U2 snRNA with “decoy” sequences upstream of their
86 productive binding site at the branch point sequence.24 In
87 addition, the drug E7107 alters the balance between alternative
88 U2 snRNA conformations, also destabilizing U2 snRNP
89 recruitment.25 Interestingly, cancer-associated SF3B1 mutations
90 induce cryptic 3′ splice site selection through the use of
91 upstream branch points.26,27 Thus, SF3B1 appears to be
92 involved in multiple interactions important for U2 snRNP
93 binding that are relevant for the control of cell proliferation and
94 apoptosis.
95 How can drugs targeting a core component of the splicing
96 machinery not result in general cellular toxicity? Tumor cells
97 often display an altered balance of alternative isoforms that
98 prevent apoptosis, promote proliferation, and invasion.28
99Transcriptome-wide analyses have identiﬁed drug-induced
100changes in alternative splicing that particularly aﬀect genes
101involved in cell division, apoptosis, and cancer progression,24
102suggesting that these compounds diﬀerentially aﬀect alternative
103splice sites. Moreover, recent results indicate that these drugs
104can have beneﬁcial therapeutic eﬀects for chronic lymphocytic
105leukemia (CLL) and for melanoma cells displaying drug
106resistance.29,30 Notably, leukemic cells with spliceosomal
107mutations display also increased sensitivity to splicing
108inhibitors.31,32
109A well-characterized alternative splicing event relevant for
110antitumor drug function involves inclusion/skipping of exon 2
111in the three-exon gene coding for myeloid cell leukemia 1
112(MCL1) proteins. This protein belongs to the Bcl-2 family of
113apoptosis regulators, displays antiapoptotic functions, and is
114overexpressed in several tumors.33−35 Due to its rapid turnover
115both at protein and at RNA levels, MCL1 is highly aﬀected by
116transcription and translation inhibitors, causing the death of
117some tumor cells depending on the levels and activity of Bcl-X,
118another alternatively spliced apoptotic regulator.35 Exon 2
119skipping leads to the production of a pro-apoptotic protein36
120and could therefore facilitate therapeutic eﬀects. Interestingly,
121recent studies show that MCL1 is highly sensitive to splicing
122inhibition, as depleting several splicing factors induces MCL1
123exon 2 skipping.37−39 Indeed, MCL1 alternative splicing was
124found to be the most aﬀected by SF3B1-targeting splicing
125inhibitors among a panel of alternative splicing events involved
126in proliferation and apoptosis control.39 Indeed, spliceostatin A
127induces apoptosis in chronic lymphocytic leukemia (CLL) cells
128through MCL1 downregulation,29 and resistant cell lines
129reacquire sensitivity to Bcl-X-targeting drugs when treated
130with meayamycin, due to MCL1 regulation.40
131Despite their very diﬀerent overall skeletons, SF3B-targeting
132molecules share a common pharmacophore,41 which includes a
133conjugated diene, an epoxide, and an oxycarbonyl group
134 f1(Figure 1). While the epoxide group was found not to be
135absolutely required for activity, it contributes to increasing
Figure 1. Chemical structure of sudemycins and variants tested in this study. The general feature of each class of modiﬁcation is indicated and
modiﬁcations highlighted in blue. Sudemycin F2 was previously described as compound 19n.47
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136 it.19,42−44 On the basis of this pharmacophore, a total synthetic
137 compound series known as sudemycins has been described.45
138 In spite of their simpliﬁed structure, containing up to six
139 sterocenters less than natural products, these drugs retain
140 potent anticancer activity in vitro and in vivo,45 as well as the
141 ability to target SF3B1.15 Previous extensive structure−activity
142 relationship (SAR) studies reported by Webb’s group led to the
143 synthesis of stable active derivatives, described as sudemycin C1
144 (cyclohexane core) and sudemycin E (dioxane core;41,45,46
145 Figure 1). Challenging synthetic hurdles included the develop-
146 ment of a synthetic route for the heterocyclic spiro moiety with
147 two stereocenters, present in all the sudemycins, and the diene
148 linker with E,E conﬁguration. The sterocenter in position 2 of
149 the pyrane ring was induced by organocatalic reduction of
150 double bond using a McMillan catalyst, and the spiroepoxide
151 was prepared by diastereoselective introduction of dimethyl-
152 sulfoxonium methylide to the ketone. The key step for
153 preparation of diene was the Julia-Kocienski oleﬁnation. In a
154 recent study,47 the synthetic route was revised, and the Julia-
155 Kocienski step was optimized by shifting the sulfone and
156 aldehyde group positions required for the oleﬁnation, which in
157 comparison to the previously described procedures resulted in
158 better diastereoselectivity and yield. Additionally, new
159 sudemycin derivatives, mostly with ester moiety modiﬁcation,
160 were reported, among them sudemycin D6, which is the most
161 potent sudemycin so far, displaying improved solubility,47
162 bearing a methylcarbamate group instead of the isobutyric
163 group present in sudemycins C1 and E (Figure 1).
164 With the aim of further exploring the chemical space of this
165 family of drugs, we have designed and synthesized several novel
166 sudemycin analogues aimed to probe key chemical features and
167 exploring possibilities for further derivatization of the structural
168 frame.
169 ■ RESULTS AND DISCUSSION
170 We aimed to test (a) the function of the conjugated diene,
171 which is part of the common pharmacophore of three classes of
172 splicing inhibitors, (b) the function of the oxycarbonyl moiety,
173 another key element of the pharmacophore, and (c) the
174 identity of the cyclohexane ring that links the previous two
175 moieties. In addition, the most active previously described
176 sudemycins D6, D1, C1, F1, F2,47 and E (Figure 1), were
177 prepared in parallel, using procedures reported by the Webb’s
178 group47 and used for biological activity comparison with the
179 new derivatives. The epoxide group was not modiﬁed in our
180 study because previous work already showed that it contributes
181 but is not absolutely required for activity.19,42−44
182 The activity of the compounds was tested in in vitro
183 biochemical assays of spliceosome (complex A) assembly and
184 in cell culture assays by assessing MCL1 alternative splicing
185 regulation and cytotoxicity. The structure of the drug variants
t1 186 and their activities are summarized in Figure 1 and Table 1,
187 respectively.
188 Conjugated Diene Modiﬁcations. Previous studies
189 indicated that the conjugated diene is important for the activity
190 of Sudemycins and other drugs.41 To test the relevance of this
191 moiety’s length, 1, the triene harboring three E conjugate
192 double bonds, and 2, a derivative harboring only one E double
193 bond, were obtained. To evaluate the importance of the
194 stereochemistry of double bonds for biological activity,
195 additional compounds 3 and 4, harboring a double bond in Z
196 conﬁguration, were also prepared.
197 s1The synthesis of triene 1 was performed (Scheme 1) using
198the known aldehyde 947 as starting material. Transformation of
199aldehyde 9 into 10 required three synthetic steps: Wittig
200elongation with Ph3PCH−CO2Et prepared in situ from
201corresponding phosphonium salt, reduction of the ester to
202allylic alcohol, and oxidation of alcohol to generate aldehyde
20310. Modiﬁed Julia-Kocienski oleﬁnation between the aldehyde
20410 and sulfone 1147 aﬀorded triene 12 with excellent
205diastereoselectivity (E/Z ratio 96:4). The transformation of
206compound 12 into 1 required the following steps: chemo-
207selective reduction of azide functional group of 12 to amine
208followed by coupling with (S,Z)-4-(tert-butyldimethylsilyloxy)-
209pent-2-enoic acid,48 alcohol deprotection, and formation of
210ester with isobutyric anhydride. During the amide formation,
211isomerization of the Z double bond in the α position was
212produced (Z/E ratio 7:3). The Z/E mixture was puriﬁed by RP-
213HPLC, and pure 1 was obtained.
214The preparation of 2 with only one double bond between the
215dioxane ring and spiro moiety started from aldehyde 1346 and
216follows a similar sequence of reactions as described for 1.
217However, the generation of oleﬁn 14 by Julia-Kocienski was not
218diastereoselective. A diasteromeric mixture of E and Z oleﬁns
219was converted to alcohol 15 in three steps, and then both
220diastereoisomers were separated using the RP-HPLC semi-
221preparative technique. Stereochemistry of E and Z double was
222assigned by 13C NMR. Sterically compressed carbon nuclei
223produce shielding eﬀects;49 thus, in Z oleﬁn, it shows a 33.7 and
22464.6 ppm chemical shift of carbons aﬀected and E oleﬁn 38.3
225and 69.1 ppm, respectively. Finally, esteriﬁcation of both
226alcohols led to corresponding isobutyric esters 2 and 3.
Table 1. Summary of Sudemycin Variants’ Activitiesa
drug
in vitro A3′ complex
formation, IC50
(nM)
MCL1 alternative
splicing regulation, IC50
(nM)
cytotoxicity in
HeLa cells, IC50
(nM)
Sud K
(7)
≈250 ≈15 2.3 ± 0.81
Sud
D6
≈500 ≈250 6.3 ± 0.82
Sud
D1
≈750 ≈630 109 ± 48
4 ≈40 000 ≈6300 12 703 ± 16 386
1 ≈30 000 ≈12 500 > 30 000
Sud
C1
≈400 ≈320 123 ± 154
Sud E ≈10 000 ≈2000 764 ± 113
Sud
F1
≈12 000 ≈3500 646 ± 38
Sud
F2
≈50 000 ≈1200 417 ± 0.00
8 n.d. ≈40 000 848 ± 200
2 n.d. > 100 000 > 30 000
3 n.d. > 100 000 n.d.
5a n.d. > 100 000 > 30 000
5b n.d. > 100 000 > 30 000
6 n.d. > 100 000 > 30 000
aSummary of activities of the compounds tested in this study.
Biochemical assays to evaluate complex A3′ formation, RT-PCR assays
to evaluate eﬀects on MCL1 alternative splicing regulation, and
cytotoxicity assays were carried out and quantiﬁed as described in the
Methods section (Supporting Information). Estimates of IC50 values
are provided. Sud: abbreviation for Sudemycin. n.d.: not detected at
the maximum concentration tested (100 μM for cytotoxicity assays, 1
mM for in vitro spliceosome assembly assay).
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227 Improved protocol of preparation of diene 16 developed by
228 Webb produces diasteromeric mixture E,E and E,Z with a ratio
229 of 9:1. In our hands, this mixture as well as TBS protected
230 alcohol could be separated by column chromatography, and a
231 pure sample of 17 was collected and converted into sudemycin
232 C1 diastereoisomer, compound 4 (Scheme 1).
233 When these derivatives were tested for activity, reduction to a
234 single double bond (in both E and Z diasteroisomer
235 conﬁgurations, 2 and 3, Figure 1) completely suppressed the
236 drug’s activity, while the 1 triene displayed highly reduced but
237 still detectable activity in splicing assays but negligible in
f2f3 238 cytotoxicity assays (Table 1, Figure 2G and H, Figure 3). On
239 the other hand, the Z,E,Z diastereomer of sudemycin C1,
240 harboring opposite stereochemistry at the double bond (4,
241 Table 1, Figures 1, 2A,B, and 3) displays lower but still
242 signiﬁcant activities (particularly in cytotoxic assays) despite the
243 dramatic change in spatial orientation of key pharmacophore
244 components (Table 1).
245 Cyclohexane Substitution by Piperazine or 1,3-
246 Dioxane. In previous studies, substitution of the cyclohexane
247 ring by a dioxane improved drug solubility.46 With the aim of
248 further increasing aqueous solubility, three novel compounds
249 harboring piperazine rings were synthesized (5a, 5b, and 6,
250 Figure 1).
251The formation of the sudemycin derivatives with a piperazine
252 s2core (Scheme 2) started from commercially available tert-butyl
2534-(2-hydroxyethyl)piperazine-1-carboxylate (18). Chain elon-
254gation of 18 and transformation into alcohol 19 as unique E
255diastereoisomers required the following: Swern oxidation of 18;
256Wittig oleﬁnation with Ph3PCH−CO2Et; and reduction of
257ester using DIBALH. Conﬁrmation of E stereochemistry was
258possible based on a lack of signals when performing 1D-NOE
259irradiation at δ = 6.8 ppm and δ = 1.8 ppm (see the Supporting
260Information). At this point, the BOC protecting group was
261removed with TFA, and free secondary amine was coupled with
262(S,Z)-4-(tert-butyldimethylsilyloxy)pent-2-enoic acid. Then,
263alcohol was oxidized with Dess-Martin periodinane, generating
26420. This aldehyde and sulfone 5 were used for Julia-Kocienski
265oleﬁnation, rendering 21 (dr 8:2). Removal of the TBS
266protecting group and esteriﬁcation with the isobutyric
267anhydride of 22 produce a mixture of ﬁnal compounds 5a
268and 5b that were separated by semipreparative RP-HPLC. In
269order to prepare carbamate 6, the diastereomeric mixture of 21
270was ﬁrst puriﬁed; then the TBS group was removed and the
271alcohol was activated as a carbonate with nitrophenylcholor-
272oformate and ﬁnally treated with methylamine to obtain the
273desired carbamate.
Scheme 1. Syntheses of 1, 2, 3, and 4a
a(a) (1-Ethoxy-1-oxopropan-2-yl)triphenylphosphonium bromide, t-BuOK, CH2Cl2, 0 °C to rt, 50%; (b) DIBALH, CH2Cl2, −78 °C, 93%; (c)
Dess-Martin periodinane, CH2Cl2, 0 °C, 70%; (d) 11, NaHMDS, THF, − 78 °C to rt, 80% for 12, 42% for 14; (e) (1) Ph3P, benzene, 55 °C; (2)
(S,Z)-4-(tert-butyldimethylsilyloxy)pent-2-enoic acid, HBTU, NEt3, ACN, 0 °C to rt 81% for 15, 75% for 17; (f) TBAF, THF, 0 °C to rt, 77% for 15,
80% for 4; (g) isobutyric anhydride, NEt3, 4-DMAP, CH2Cl2, 0 °C 79% for 2, 76% for 3, 80% for 4; (h) RP-HPLC semipreparative separation. Bt =
2-benzo[d]thiazole
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Figure 2. In vitro spliceosome (A3′ complex) formation assays. (A) Representative Phosphoroimager pictures of electrophoretic separation of H and
A3′ complexes assembled upon incubation of a radioactively labeled adenovirus major late promoter RNA (spanning sequences corresponding to 3′
half of intron 1 and part of the following exon) in HeLa nuclear extracts and fractionation on nondenaturing agarose gels. The electrophoretic
mobility of A3′ and H complexes is indicated, as well as concentrations of the indicated drugs (1 and 4, conjugate diene variants) or DMSO as
control. Only complex H is formed in the absence of ATP. (B) Quantiﬁcation of the percentage of A3′ complex formation for a range of
concentrations of the indicated drugs, corresponding to the results reported in A. (C) Results equivalent to those in A, for sudemycins D6 and K.
(D) Quantiﬁcation of the results reported in C, as in B. (E) Analyses as in A for the indicated drugs and concentrations. The goal of the experiment
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274 These compounds showed very low activity in splicing or cell
275 proliferation tests and no detectable activity in in vitro assays,
276 revealing the requirement of the cyclohexane ring for
277 sudemycin’s function (Table 1, Figures 2G,H and 3). In
278 agreement with previous results,47 substitution of sudemycin
279 D6 cyclohexyl group by a dioxane also reduced strongly the
280 drug’s activity (sudemycin F2,47 Figure 1 and Table 1, Figure 3,
281 Supporting Information Figure 1A and C).
282 Oxycarbonyl group modiﬁcations: Sudemycin K. The
283 oxycarbonyl group is another key element of the common
284 pharmacophore. As reported by Webb and colleagues,46 a free
285 alcohol at this position dramatically decreases the activity
286 compared to ester derivatives. To further explore other
287 chemical moieties at this position, we prepared compounds
288 with amide or carbamate groups instead of ester (sudemycin K
289 or 7 and 8, Figure 1). As amide groups are less susceptible to
290 hydrolysis than ester groups, these compounds might display
291 higher stability and eﬃcacy.
292 Sudemycin K was obtained by reaction of the acid 27 with
293 the amine previously obtained in the reduction of azide 16
s3 294 (Scheme 3). The acid 27 was obtained from commercially
295 available L-alanine methyl ester hydrochloride by trans-
296 formation into amide 24 followed by ester reduction to
297 aldehyde 25. Oleﬁnation of 25 to give Z-26 was achieved using
298 Still-Gennari protocol with good diastereoselectivity (dr =
299 92:8). The hydrolysis of ester Z-26 using conventional methods
300 (LiOH, NaOH) led to decomposition; however, using milder
301 reagents like trimethyltin hydroxide, the desired acid with
302 moderate yield was obtained. Acid 30 needed for the
303 preparation of carbamate 8 was obtained in a similar way
304 (Scheme 3) starting from commercial aldehyde 28. The main
305 advantage of this synthetic process lies in greater convergence
306 and fewer synthetic steps than previously described, with a
307 similar yield.
308 Replacing the oxycarbonyl by an amide group (sudemycin K,
309 Figure 1) resulted in a compound with higher activity than
310 sudemycin D6, the most potent sudemycin described so far,
311 both in biochemical spliceosome assembly assays as well as in
312 cellular assays for MCL1 alternative splicing and for cytotoxicity
313 (Table 1, Figures 2C−F and 3). The solubility of sudemycin K
314 and D6 was found to be comparable (Supporting Information).
315 Because the higher activity of sudemycin K was observed both
316 in short-term alternative splicing regulation of MCL1 and in
317 long-term increased cytotoxicity assays, the improved activity is
318 likely contributed both by direct eﬀects on the splicing
319 machinery and by improved cell permeability or in vivo
320 stability. The replacement of the ester by an amide group could
321 make sudemycin K less sensitive to esterases, present for
322 example in plasma and microsomes50 and believed to be the
323 main factor responsible for the observed short in vivo half-life of
324 sudemycin C1.45 Indeed, we observed higher stability of this
325 compound upon incubation in culture medium containing fetal
f4 326 bovine serum (Figure 4). Replacing the isopropyl by a
327 carbamate (8, Figure 1) strongly reduced the compound
328 activity to levels undetectable in in vitro biochemical assays and
329very lowbut still detectablein cytotoxicity and alternative
330splicing switching assays (Table 1, Figures 2G,H and 3).
331Structure−Function Insights. Webb and colleagues
332proposed that, despite their structural variety, natural
333compounds targeting the SF3B complex share a common
334pharmacophore structure.41 The pharmacophore was repeated
335in the synthetic sudemycins that, in contrast with natural
336compounds, are suitable for scalable production and display
337improved stability and solubility.45,47 The common pharmaco-
338phore hypothesis is also supported by recent results arguing
339that herboxidiene, spliceostatin A, and pladienolide B bind to
340the same site in the SF3B complex and likely share a common
341inhibitory mechanism.51
342A conjugated diene is one of the three key features of the
343common pharmacophore.41 Cyclopropyl modiﬁcations in this
344moiety were shown to reduce but not suppress the activity of
345meayamycin’s variants, suggesting that the diene needs to be in
346trans conﬁguration.52 We conﬁrmed that conversion of the
347diene to a single double bond suppresses activity. Surprisingly,
348we also found that both the compound harboring a triene
349moiety and the stereoisomer displaying a Z,E,Z conﬁguration
350retained some activity (particularly the latter in cytotoxicity
351assays). This result reveals spatial ﬂexibility around the
352conjugated diene moiety, particularly regarding the relative
353orientation of the oxane ring and its associated epoxi group, as
354well as its spatial relationship with the oxycarbonyl moiety
355(another key feature of the pharmacophore) at the other end of
356the molecule. Interestingly, the Z,E,Z conﬁguration opens the
357possibility of versatile modiﬁcation routes through Diels−Alder
358reactions.
359We also conﬁrmed the need of cyclohexane or dioxane rings
360for activity, with cyclohexane-containing drugs being more
361active. The more planar structure of piperazine disrupts a drug’s
362activity, suggesting that the spatial conﬁguration of this moiety
363is essential to displaying a proper orientation of the oxycarbonyl
364and conjugated diene groups in the functional pharmacophore.
365Substitution of the cyclohexyl group by a dioxane also reduced
366strongly the drug’s activity, further supporting the importance
367of this structure.
368The introduction of an amide group instead of the ester led
369to a compound with improved splicing inhibitory activity and
370cytotoxicity. While we only analyzed this variant in the context
371of sudemycin molecules, we hypothesize that a similar
372modiﬁcation can have similar enhancing eﬀects on the activity
373of the other classes of compounds harboring a similar
374pharmacophore, including pladienolides, herboxidienes, and
375FR901464.
376Given that compounds from parallel synthesis of the various
377sudemycin analogs were tested, the higher activity of sudemycin
378K can be attributed to the amide group and be associated both
379with stronger direct eﬀects on the splicing machinery, e.g.,
380improved aﬃnity for the target, and with higher solubility and/
381or stability. As the solubility was found to be comparable to that
382of sudemycin D6, the results of Figure 4 indeed argue for
383improved stability, as expected if replacement of the oxy-
Figure 2. continued
was to compare in parallel the diﬀerent concentrations of various drugs causing a 50% decrease in A3′ complex formation. (F) Quantiﬁcations of
results as in E, corresponding to triplicate experiments. Diﬀerences between drugs were not signiﬁcant (t test), while they were all signiﬁcantly
diﬀerent from the control DMSO treatment (p value < 0.01). Standard deviations are indicated. (G) Analyses as in E at 1 mM drug concentrations
(maximal concentrations tested). (H) Quantiﬁcation of results as in G, corresponding to triplicate experiments. Drug eﬀects were not signiﬁcantly
diﬀerent from control DMSO treatment (t test). Standard deviations are indicated.
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Figure 3. MCL1 alternative splicing and cytotoxicity assays in HeLa cells. (A) Capillary electrophoresis proﬁles of RT-PCR ampliﬁcation of MCL1
alternatively spliced products from RNA isolated 3 h after drug exposure. The positions of the products corresponding to exon 2 inclusion and
skipping are indicated, along with the drug treatment and concentrations (DMSO, control without drug). One representative example per condition
is shown. (B) Quantiﬁcation of data shown in A for duplicate experiments. Graphs represent % of MCL1 exon 2 inclusion at diﬀerent drug
concentrations, as indicated. Drug treatments were clustered according to the diﬀerent concentration ranges at which they induce exon 2 skipping.
Standard deviations are shown. Higher activity of sudemycin K than sudemycin D6 was signiﬁcant (t test, p value < 0.01). (C) Cytotoxicity assays.
Cell viability was measured using Resazurin assays 72 h after drug exposure. Graphs indicate the fraction of living cells compared to control DMSO
treatment. All treatments were performed in triplicate, and standard deviations are shown. Drug treatments were clustered according to the diﬀerent
concentration ranges at which they induce signiﬁcant decreases in cell viability. Higher activity of sudemycin K than sudemycin D6 was signiﬁcant (t
test, p value < 0.01).
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384 carbonyl by an amide group makes it no longer a substrate of
385 esterases, believed to be the main factor responsible for the
386 short half-life of sudemycin C1 in vivo.45,47 Jurica and colleagues
387 recently showed that both active compounds and their inactive
388 analogues compete for binding to the same site, suggesting that
389 the compounds’ activities may rely upon a conformational
390change within the SF3B complex induced (or prevented) only
391by the active variants.51 Therefore, the diﬀerent activity of
392sudemycin variants, including the higher activity of sudemycin
393K, may be also due to more eﬃcient modulation of such
394conformational changes.
395The amide moiety makes sudemycin K suitable for
396conjugation with ureas, amides, and carbamates, potentially
397generating a large variety of chemical derivatives, which once
398again might be extrapolable to other families of splicing
399inhibitors, like meayamycin, spliceostatin, and pladienolides.
400Future work will focus on the generation and activity evaluation
401of such derivatives.
402In summary, in addition to conﬁrming the importance of the
403conjugated diene, our studies reveal that changes in the diene
404conﬁguration only partially decrease drug activity, while
405replacement of a cyclohexane ring by piperazine abolishes it.
406Finally, we obtained a compound with improved activity, at
407least partly due to increased stability, sudemycin K, by replacing
408the oxycarbonyl with an amide group. This variant oﬀers
409reactivity possibilities that can potentially expand signiﬁcantly
410the structural diversity of these drugs.
411■ METHODS
412Synthesis methods are summarized in the legends of Schemes 1−3 and
413fully detailed, along with the characterization of synthetic products by
414NMR and 2D correlation spectra, in the Supporting Information.
415Biochemical and cellular assays were described before24,39 and fully
416detailed in the Supporting Information.
417■ ASSOCIATED CONTENT
418*S Supporting Information
419The Supporting Information is available free of charge on the
420ACS Publications website at DOI: 10.1021/acschem-
421bio.6b00562.
Scheme 2. Syntheses of 5a, 5b, and 6a
aReagents and conditions: (a) (COCl)2, DMSO, CH2Cl2, −78 °C,
then Et3N −78 °C to rt; (b) (1-ethoxy-1-oxopropan-2-yl)triphenyl-
phosphonium bromide, t-BuOK, CH2Cl2, 0 °C to rt 65% (2 steps); (c)
DIBALH, CH2Cl2, −78 °C, 78%; (d) TFA, CH2Cl2, 0 °C to rt; (e)
(S,Z)-4-(tert-butyldimethylsilyloxy)pent-2-enoic acid, HBTU, NEt3,
ACN, 0 °C to rt, 90% (2 steps); (f) Dess-Martin periodinane, CH2Cl2,
0 °C, 78%; (g) 11, NaHMDS, THF, − 78 °C to rt, 70%; (h) TBAF,
THF, 0 °C to rt, 67%; (i) semipreparative RP-HPLC puriﬁcation; (j)
isobutyric anhydride, NEt3, 4-DMAP, CH2Cl2, 0 °C, 98%; (k) 4-
nitrophenyl chloroformate, NEt3, CH2Cl2, 0 °C to rt, 45%; (l)
methylamine, ClCH2CH2Cl, 0 °C to rt, 75%.
Scheme 3. Synthesis of Sudemycin K and 8a
aReagents and conditions: (a) Isobutyric anhydride, NEt3, 4-DMAP,
CH2Cl2, 0 °C, 99%; (b) DIBALH, toluene, −78 °C, 71%; (c)
K HMD S , 1 8 - c r o w n - 6 , b i s ( 2 , 2 , 2 - t r i ﬂ u o r o e t h y l )
(methoxycarbonylmethyl)phosphonate, THF, −78 °C, 82% for 26,
72% for 29; (d) Me3SnOH, ClCH2CH2Cl, 85 °C, 50% for 29, 75% for
30; (e) (1) 16, Ph3P, benzene, 55 °C; (2) acid 27 or 30, HBTU, NEt3,
ACN, 0 °C to rt, 30% (2 steps) for 7, 50% (2 steps) for 8. The overall
yield of sudemycin K synthesis was 12%, comparable to previous yields
obtained for other Sudemycin variants.45−47
Figure 4. Stability of sudemycin D6 and sudemycin K upon incubation
in culture medium with 10% fetal bovine serum. Complete culture
medium containing 1 μM drug or the equivalent volume of DMSO
was incubated at 37 °C for the indicated times and subsequently added
to a lawn of HeLa cells. After 3 h of incubation, RNA was isolated and
MCL1 alternative splicing was assessed as a measure of residual drug
activity. Exon 2 inclusion levels upon DMSO treatment were used to
normalize values across time points, and the levels of regulation
induced at the 0 h time point by each drug were set at 100%. The
reduction of the eﬀects at each time point is signiﬁcantly lower for
sudemycin K compared to sudemycin D6 (p value < 0.02 at 24h, p
value < 0.001 at 48 h by t test comparison of duplicated treatments).
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